

**NCBI** PubMed

PubMed QUERY

PubMed



Other Formats: [Citation](#) [MEDLINE](#)  
Links: [Related Articles](#)

Order this document

*Ann Oncol* 1996 Apr;7(4):347-53

## A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.

**Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD**

University of Texas Health Science Center at San Antonio, USA.

**PURPOSE:** To assess the effect of gemcitabine in patients with metastatic pancreas cancer that had progressed despite prior treatment with 5-FU. **PATIENTS AND METHODS:** Seventy-four patients were enrolled in this multicenter trial. Alleviation of cancer-related symptoms was the primary endpoint. Sixty-three patients completed a pain stabilization period and were treated with gemcitabine. Clinical Benefit Response was defined as a > or = 50% reduction in pain intensity, > or = 50% reduction in daily analgesic consumption, or > or = 20 point improvement in KPS that was sustained for > or = 4 consecutive weeks. **RESULTS:** Seventeen of 63 pts (27.0%) attained a Clinical Benefit Response (95% CI: 16.0%-38.0%). The median duration of Clinical Benefit Response was 14 weeks (range: 4-69 weeks). Median survival for patients treated with gemcitabine was 3.85 months (range: 0.3-18.0+ months). Therapy was generally well-tolerated with a low incidence of grade 3 or 4 toxicities. **CONCLUSION:** Systematic assessment of subjective outcomes can be used to evaluate the clinical impact of new therapies for pancreas cancer, a highly symptomatic disease. Our findings suggest that gemcitabine is a useful palliative agent in patients with 5-FU-refractory pancreas cancer.

### Publication Types:

- Clinical trial
- Clinical trial, phase ii
- Multicenter study

### Comments:

- Comment in: *Ann Oncol* 1996 Apr;7(4):333-4
- Comment in: *Ann Oncol* 1996 Apr;7(4):335-7

PMID: 8805925, UI: 96399432



the above report in [Macintosh](#) [Text](#) format